01 Nov, 2023 Bristows’ SnippITs – As the old phrase goes, Never Assume! – it’s commercial common sense By Adrian Sim This post is part of the Bristows’ SnippITs series, which pulls together the key practical takeaways from recent court decisions for the...
25 Oct, 2023 Bristows’ SnippITs – Make sure your drafting is tip-“Topalsson” By Adrian Sim Vivien Zhu This post is part of the Bristows’ SnippITs series, which pulls together the key practical takeaways from recent court decisions for the...
12 Oct, 2023 Guide to doing business in the UK By Emily Atkinson Samuel Munday Harry Woodcock This note provides a high-level overview of some of the key issues to consider when a non-UK business plans to expand into the UK.
20 Sep, 2023 My supplier is using AI in the delivery of its services: considerations for in-house lawyers By Rob Powell As software tools and solutions powered by AI become more prevalent and accessible, they are more frequently being used “in the...
18 Sep, 2023 First CRISPR therapy seeks regulatory approval, but will it be able to avoid the pitfalls of other cell and gene therapies? By Janna Lawrence Claire Smith Ellen Lambrix This article discusses the first CRISPR therapy seeks regulatory approval, raising the question but will it be able to avoid the pitfalls...
05 Jul, 2023 Spin-out trends: Views from the PraxisAuril conference By Erik Müürsepp Last month Adam Coughlin and Erik Müürsepp from Bristows’ Commercial IP team had the opportunity to attend the annual conference of...
26 May, 2023 UK signs the Singapore Convention on Mediation By Ben Coleman Dhara Reddy The UK government has this month signed the United Nations Convention on International Settlement Agreements Resulting from Mediation...
25 May, 2023 BioIntegrates 2023: Biotech pinch points and strategic decisions By Ellen Lambrix Ellen Lambrix and Adam Coughlin from Bristows' Commercial IP team attended the BioIntegrates conference in London on 16 May 2023. With...
11 Apr, 2023 Bristows' SnippITs – Novation Dis-Astra: Agreement novated by conduct despite a requirement for written consent and NOM clause By Sean Hess This post is part of the Bristows’ SnippITs series, which pulls together the key practical takeaways from recent court decisions for the...
27 Mar, 2023 Cell and gene therapy platforms licensing – exclusivity and carving-up fields By Louisa Jacobs Cell and gene therapies (CGTs) are highly complex and sophisticated technologies with a lot of constituent parts. To bring a product to...
20 Feb, 2023 Platform technology collaborations – who owns the arising IP? By Louisa Jacobs Claire Smith Platform technologies, often the core business of a biotech or techbio company, can be extremely valuable assets. Whether it’s a high...
03 Feb, 2023 High risk, high reward funding: will ARIA have researchers singing for joy? By Ellen Lambrix On 26 January 2023, Science Minister George Freeman announced the formal establishment of the Advanced Research and Invention Agency...